share_log

Globus Medical (NYSE:GMED) Stock Rating Upgraded by StockNews.com

Globus Medical (NYSE:GMED) Stock Rating Upgraded by StockNews.com

股票新聞網站上調了Globus Medical(紐約證券交易所代碼：GMED)的股票評級
kopsource ·  2022/08/15 23:11

Globus Medical (NYSE:GMED – Get Rating) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Monday.

在週一發佈給客户和投資者的一份研究報告中，股票研究分析師將Globus Medical(紐約證券交易所代碼：GMED-GET Rating)的評級從持有上調至買入。

A number of other research firms have also recently issued reports on GMED. Piper Sandler cut their price objective on shares of Globus Medical from $80.00 to $75.00 and set an "overweight" rating on the stock in a research report on Friday, August 5th. BTIG Research decreased their price objective on shares of Globus Medical to $71.00 in a research note on Tuesday, August 9th. Morgan Stanley reduced their target price on shares of Globus Medical from $68.00 to $62.00 and set an "equal weight" rating for the company in a research report on Friday, July 15th. Wells Fargo & Company cut their price objective on shares of Globus Medical from $80.00 to $70.00 in a report on Wednesday, May 11th. Finally, Canaccord Genuity Group cut their price objective on shares of Globus Medical from $80.00 to $75.00 in a report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $77.36.

其他一些研究公司最近也發佈了關於GMED的報告。派珀·桑德勒在8月5日星期五的一份研究報告中將Globus Medical的股票目標價從80.00美元下調至75.00美元，並對該股設定了“增持”評級。BTIG Research在8月9日星期二的一份研究報告中將Globus Medical的股票目標價下調至71.00美元。摩根士丹利在7月15日(週五)的一份研究報告中將Globus Medical的股票目標價從68.00美元下調至62.00美元，併為該公司設定了“同等權重”的評級。富國銀行在5月11日星期三的一份報告中將Globus Medical的股票目標價從80.00美元下調至70.00美元。最後，在5月11日星期三的一份報告中，Canaccel Genuity Group將Globus Medical的股票目標價從80.00美元下調至75.00美元。一名投資分析師對該股的評級為持有，9名分析師對該公司的評級為買入。根據MarketBeat的數據，該股目前的普遍評級為“適度買入”，平均目標價為77.36美元。

Get
到達
Globus Medical
Globus Medical
alerts:
警報：

Globus Medical Price Performance

Globus醫療價格表現

Shares of Globus Medical stock traded up $0.87 during trading on Monday, hitting $67.54. The company's stock had a trading volume of 447,187 shares, compared to its average volume of 704,046. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of 45.33, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The stock has a 50-day moving average price of $58.49 and a two-hundred day moving average price of $65.36. Globus Medical has a 52 week low of $52.60 and a 52 week high of $84.23.

在週一的交易中，Globus Medical的股價上漲了0.87美元，達到67.54美元。該公司股票的成交量為447,187股，而其平均成交量為704,046股。該股市值為67.2億美元，市盈率為45.33倍，市盈率為3.19倍，貝塔係數為1.13。該股的50日移動均線價格為58.49美元，200日移動均線價格為65.36美元。Globus Medical的52周低點為52.60美元，52周高點為84.23美元。

Institutional Trading of Globus Medical

Globus Medical的制度性交易

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its position in Globus Medical by 0.7% during the first quarter. BlackRock Inc. now owns 7,347,858 shares of the medical device company's stock valued at $542,124,000 after purchasing an additional 48,913 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its position in Globus Medical by 125.8% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 4,562,730 shares of the medical device company's stock valued at $256,152,000 after purchasing an additional 2,542,264 shares during the period. Wellington Management Group LLP increased its position in Globus Medical by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 3,236,599 shares of the medical device company's stock valued at $238,796,000 after purchasing an additional 20,375 shares during the period. State Street Corp increased its position in Globus Medical by 2.9% during the 1st quarter. State Street Corp now owns 2,219,112 shares of the medical device company's stock valued at $163,726,000 after purchasing an additional 62,156 shares during the period. Finally, Champlain Investment Partners LLC grew its position in shares of Globus Medical by 7.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,757,735 shares of the medical device company's stock worth $126,908,000 after buying an additional 123,500 shares during the last quarter. 67.19% of the stock is owned by hedge funds and other institutional investors.
一些對衝基金和其他機構投資者最近調整了對該公司的持股。今年第一季度，貝萊德將其在Globus Medical的持股比例提高了0.7%。貝萊德股份有限公司在上季度增持了48,913股後，目前持有這家醫療器械公司7,347,858股股票，價值542,124,000美元。凱恩·安德森·魯德尼克投資管理公司在第二季度將其在Globus Medical的持倉增加了125.8%。Kayne Anderson Rudnick Investment Management LLC在此期間又購買了2,542,264股，現在擁有這家醫療設備公司4,562,730股股票，價值256,152,000美元。惠靈頓管理集團LLP在第一季度將其在Globus Medical的頭寸增加了0.6%。惠靈頓管理集團(Wellington Management Group LLP)在此期間額外購買了20,375股惠靈頓醫療器械公司的股票，目前持有該公司3,236,599股股票，價值238,796,000美元。道富集團在第一季度將其在Globus Medical的頭寸增加了2.9%。道富集團目前持有這家醫療設備公司2,219,112股票，價值163,726,000美元，在此期間又購買了62,156股票。最後，尚普蘭投資夥伴有限責任公司在第四季度將其在Globus Medical的股票頭寸增加了7.6%。尚普蘭投資夥伴有限責任公司現在擁有這家醫療設備公司1,757,735股票，價值126,908,000美元，在上個季度額外購買了123,500股票。67.19%的股票由對衝基金和其他機構投資者持有。

Globus Medical Company Profile

Globus醫療公司簡介

(Get Rating)

(獲取評級)

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.

Globus Medical，Inc.是一家醫療設備公司，為美國和國際上的肌肉骨骼疾病患者開發和銷售保健解決方案。它提供脊柱產品，例如用於治療退變、畸形、腫瘤和創傷條件的傳統融合植入物，包括椎弓根螺釘和棒系統、鋼板系統、椎間間隔器和椎體切除設備；運動保護技術的治療選項，包括動態穩定、全椎間盤置換和棘間牽張設備；用於治療椎體壓縮骨折的介入性疼痛管理解決方案；以及由同種異體移植物和合成替代品組成的再生生物產品。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Globus Medical (GMED)
  • The Five Hottest Calls From The Q2 Earnings Season
  • Here is a Simple 4 Stock Portfolio that Can Outperform the Market
  • Is AMC Entertainment Pulling a Fast One on the APEs?
  • Here's How the Inflation Reduction Act Energizes Power Stock
  • The Institutions Trim Holdings Of High-Yielding Foot Locker, Inc
  • 免費獲取StockNews.com關於Globus Medical(GMED)的研究報告
  • 第二季度財報季最熱門的五個電話
  • 以下是一個簡單的4只股票投資組合，它可以跑贏大盤
  • AMC娛樂公司是在對猩猩採取快速行動嗎？
  • 以下是《降低通脹法案》如何提振電力庫存
  • 機構調整高收益Foot Locker，Inc.的控股

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Globus醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Globus Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論